Bis-quinolinium cyclophanes: 6, 10-diaza-3(1, 3), 8(1, 4)-dibenzena-1, 5(1, 4)diquinolinacyclodecaphane (UCL 1684), the first nanomolar, non-peptidic blocker of the apamin-sensitive Ca2+-activated K+ channel

Journal of Medicinal Chemistry

Volumn 41, Issue 1, 1998, Pages 2-5

  Rosa, Joaquin Campos ^a   Galanakis, Dimitrios ^b   Ganellin, C Robin ^c   Dunn, Philip M ^a   Jenkinson, Donald H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GRANADA   (Spain)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANE; APAMIN; CALCIUM ACTIVATED POTASSIUM CHANNEL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; QUINOLINE DERIVATIVE; SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; UCL 1684;

ANIMAL; ARTICLE; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; HUMAN; OOCYTE; PHYSIOLOGY; RAT; STRUCTURE ACTIVITY RELATION; XENOPUS LAEVIS;

ALKANES; ANIMALS; APAMIN; BRAIN; HUMANS; MOLECULAR STRUCTURE; OOCYTES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; QUINOLINIUM COMPOUNDS; RATS; SMALL-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOPUS LAEVIS;

EID: 0031603012     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970571a     Document Type: Article

References (41)

1. (a) Haylett, D. G.; Jenkinson, D. H. In Potassium Channels; Cook, N. S., Ed.; Ellis Horwood Limited: Chichester, 1990; pp 70-95.
2. + channel: Molecular properties, differentiation, involvement in muscle disease, and endogenous ligands in mammalian brain. Handb. Exp. Pharmacol. 1988, 83, 135-145.
3. (a) Renaud, J. F.; Desnuelle, C.; Schmid-Antomarchi, H.; Hugues, M.; Serratrice, G.; Lazdunski, M. Expression of apamin receptor in muscles of patients with myotonic muscular dystrophy. Nature 1986, 379, 678-680.
4. (b) Behrens, M. I.; Vergara, C. Increase of apamin receptors in skeletal muscle induced by colchicine: possible role in myotonia. Am. J. Physiol. 1992, 263, C794-C802.
5. + channels in myotonic dystrophy. Muscle Nerve 1994, 17, 1264-1270.
6. + channels, on learning and memory processes. Brain Res. 1991, 551, 322-326.
7. (b) Belcadi-Abbassi, W.; Destrade, C. Post-test apamin injection suppresses a Kamin-like effect following a learning session in mice. NeuroReport 1995, 6, 1293-1296.
8. Benington, J. H.; Woudenberg, M. C.; Heller, H. C. Apamin, a selective SK potassium channel blocker, suppresses REM sleep without a compensatory rebound. Brain Res. 1995, 692, 86-92.
9. Yamamoto, H.-A.; Harris, R. A. Calcium-dependent 86Rb efflux and ethanol intoxication: Studies of human red blood cells and rodent brain synaptosomes. Eur. J. Pharmacol. 1983, 88, 357-363.
10. (a) Banks, B. E. C.; Brown, C.; Burgess, G. M.; Burnstock, G.; Claret, M.; Cocks, T. M.; Jenkinson, D. H. Apamin blocks certain neurotransmitter-induced increases in potassium permeability. Nature 1979, 282, 415-417.
11. (b) Burgess, G. M.; Claret, M.; Jenkinson, D. H. Effects of quinine and apamin on the calciumdependent potassium permeability of mammalian hepatocytes and red cells. J. Physiol. 1981, 377, 67-90.
12. + channels. Cell Calcium 1983, 4, 421-428.
13. + channels. J. biol. Chem. 1990, 265, 4753-4759.
14. Zerrouk, H.; Mansuelle, P.; Benslimane, A.; Rochat, H.; MartinEauclaire, M. F. Characterization of a new leiurotoxin I-like scorpion toxin PO5 from Androctonus mauretanicus mauretanicus. FEBS Lett. 1993, 320, 189-192.
15. Legros, C.; Oughuideni, R.; Darbon, H.; Rochat, H.; Bougis, P. E.; Martin-Eauclaire, M.-F. Characterisation of a new peptide from Tityus serrulatus scorpion venom which is a ligand of the apamin-binding site. FEBS Lett. 1996, 390, 81-84.
16. (a) Jenkinson, D. H.; Haylett, D. G.; Cook, N. S. Calciumactivated potassium channels in liver cells. Cell Calcium 1983, 4, 429-437.
17. + channel of the bullfrog sympathetic ganglion cell. Brain Res. 1984, 301, 146-148.
18. Cook, N. S.; Haylett, D. G. Effects of apamin, quinine and neuromuscular blockers on calcium-activated potassium channels in guinea pig hepatocytes. J. Physiol. 1985, 358, 373-394.
19. + channels in hepatocytes and of nicotinic responses in skeletal muscle. Eur. J. Pharmacol. 1993, 236, 201-207.
20. (b) Dunn, P. M. Dequalinium, a selective blocker of the slow afterhyperpolarization in rat sympathetic neurones in culture. Eur. J. Pharmacol. 1994, 252, 189-194.
21. (a) Dunn, P. M.; Davis, C. A.; Ganellin, C. R.; Haylett, D. G.; Morgan, J. M.; Jenkinson, D. H. Potassium channel blocking activity of dequalinium analogues in guinea-pig hepatocytes and rat sympathetic neurones. Br. J. Pharmacol. 1991, 104, 165P.
22. (b) Galanakis, D.; Davis, C. A.; Del Rey Herrero, B.; Ganellin, C. R.; Dunn, P. M.; Jenkinson, D. H. Synthesis and structureactivity relationships of dequalinium analogues as K+ channel blockers. Investigations on the role of the charged heterocycle. J. Med. Chem. 1995, 38, 595-606.
23. 2 group. Bioorg. Med. Chem. Lett. 1995, 5, 559-562.
24. + channel blockers: Investigation into the role of the substituent at position 4 of the quinoline ring. J. Med. Chem. 1995, 38, 3536-3546.
25. + channel blockers related to dequalinium. J. Med. Chem. 1996, 39, 359-370.
26. + channel: Variation of the length of the alkylene chain. J. Med. Chem. 1996, 39, 3592-3595.
27. + channel-blocking activity of dequalinium analogues having semirigid linkers. J. Med. Chem. 1996, 39, 4247-4254.
28. ca channel blockers: Synthesis, pharmacological testing and radioligand binding studies on mono-, bis- and tris-quinolinium compounds. Arch. Pharm.-Pharm. Med. Chem. 1996, 329, 524-528.
29. + channel. Bioorg. Med. Chem. Lett. 1997, 7, 7-10.
30. + channels. Br. J. Pharmacol. 1994, 112, 131P.
31. + channels by gallamine and a novel bis-quaternary quinolinium cyclophane, UCL 1530. Br. J. Pharmacol. 1996, 117, 35-42.
32. + channels. J. Biol. Chem. 1994, 269, 18053-18061.
33. + channels. Biochemistry 1996, 35, 7917-7927.
34. Köhler, M.; Hirschberg, B.; Bond, C. T.; Kinzie, J. M.; Marrion, N. V.; Maylie, J.; Adelman, J. P. Small-conductance, calciumactivated potassium channels from mammalian brain. Science 1996, 273, 1709-1714.
35. (a) Szendey, G. L.; Munnes, S. Konstitution und eigenschaften des biphenylen-(4, 4′)-bis-[methylatropiniumbromids], einer biquartären atropinverbindung. (Constitution and properties of biphenylene-(4, 4′)-bis[methylatropinium] bromide, a bisquaternary atropinium compound.) Chem. Ber. 1961, 94, 38-42.
36. (b) Staab, H. A.; Haenel, M. Synthesen von [2.2](4, 4′)biphenylophan, [2.2](2, 7)phenanthrenophan und [2](4, 4′)biphenylo[2](2, 7)phenanthrenophan (Synthesis of [2.2](4, 4′)biphenylophane, [2.2](2, 7)-phenanthrenophane and [2](4, 4′)biphenylo[2](2, 7)phenanthrenophane). Chem. Ber. 1973, 106, 2190-2202.
37. Cram, D. J.; Steinberg, H. Macro rings. I. Preparation and spectra of the paracyclophanes. J. Am. Chem. Soc. 1951, 73, 5691-5704.
38. (a) Braun, V. Die einwirkung flüssigen ammoniaks auf organische halogenverbindungen. (The action of liquid ammonia on organic halogen compounds.) Chem. Ber. 1937, 70, 979-993
39. (b) Albert, A.; Mills, J. A.; Royer, R. Benzylamine analogues of chemotherapeutic diamidines. J. Chem. Soc. 1947, 1452-1455.
40. Gornostaeva, S. E.; Kornev, K. A. Aminomethylation of some aromatic compounds Ukrain. Khim. Zh. (Russ. Ed.) 1960, 26, 227-232;
41. Chem. Ahstr. 1960, 24473g.